Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

Investor Relations

About InMed Pharmaceuticals:

InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s disease and ocular and dermatological indications.

Robust R&D pipeline of small molecule therapeutics

    • Three programs in Alzheimer’s disease, AMD and epidermolysis bullosa
    • Completed Phase 2 epidermolysis bullosa program, currently seeking partnerships
    • Library of proprietary analogs targeting diverse pharmaceutical applications

Alzheimer’s drug candidate demonstrating a multi-factorial approach

    • Preclinical studies demonstrate neuroprotective effects, reduction in neuroinflammation and an ability to extend the length of neurites
    • Oral administration confirmed

Revenue-generating subsidiary

    • Diverse product portfolio of bioidentical non-intoxicating rare cannabinoids
    • Selling cannabinoids to the H&W industry

Strong patent position

    • 13 patent families
    • Broad range of IP across molecules, manufacturing, formulations and methods of use

Experienced team with a successful track record

    • Extensive experience from drug discovery to commercialization
    • Pharmaceutical R&D and manufacturing

Latest News

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

June 27, 2025
Read More »

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

June 25, 2025
Read More »

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

June 24, 2025
Read More »
See All News

Latest Presentation

View All Presentations

Investor Alerts

Sign up for investor alerts!
Sign Up

Information Request

Send us a request for information
Learn More
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*